Literature DB >> 32140482

An updated scoring system for prediction of survival after resection of colorectal liver metastases: addition of KRAS status as an important risk modifier.

Evan Jost1, Don Major1, Elijah Dixon1.   

Abstract

Entities:  

Year:  2020        PMID： 32140482      PMCID： PMC7026785          DOI： 10.21037/hbsn.2019.06.06

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  7 in total

1.  Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.

Authors:  Ronald Lieberman
Journal:  Am J Ther       Date:  2012-11       Impact factor: 2.688

2.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

3.  RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.

Authors:  Kristoffer W Brudvik; Robert P Jones; Felice Giuliante; Junichi Shindoh; Guillaume Passot; Michael H Chung; Juhee Song; Liang Li; Vegar J Dagenborg; Åsmund A Fretland; Bård Røsok; Agostino M De Rose; Francesco Ardito; Bjørn Edwin; Elena Panettieri; Luigi M Larocca; Suguru Yamashita; Claudius Conrad; Thomas A Aloia; Graeme J Poston; Bjørn A Bjørnbeth; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2019-01       Impact factor: 12.969

4.  Major hepatic resection for metachronous metastases from colon cancer.

Authors:  B Cady; W V McDermott
Journal:  Ann Surg       Date:  1985-02       Impact factor: 12.969

Review 5.  Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy.

Authors:  Robert P Jones; Graeme J Poston
Journal:  Annu Rev Med       Date:  2016-09-28       Impact factor: 13.739

Review 6.  Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Fabio Bagante; Demetrios Moris; Jordan Cloyd; Eleftherios Spartalis; Timothy M Pawlik
Journal:  Surg Oncol       Date:  2018-05-08       Impact factor: 3.279

7.  RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.

Authors:  Giuseppe Zimmitti; Junichi Shindoh; Yoshihiro Mise; Scott Kopetz; Evelyne M Loyer; Andreas Andreou; Amanda B Cooper; Harmeet Kaur; Thomas A Aloia; Dipen M Maru; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2014-09-17       Impact factor: 5.344
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.